Breast/lung cancer
1 – 10 of 44
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
- Contribution to journal › Article
-
Mark
Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation
- Contribution to journal › Article
-
Mark
Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer
- Contribution to journal › Article
-
Mark
Dynamic assessment of proliferation to guide response-adapted therapy in the setting of neoadjuvant chemotherapy in ER+/HER2- breast cancer
- Contribution to journal › Article
- 2025
-
Mark
Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
- Contribution to journal › Article
-
Mark
Multi-omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma
- Contribution to journal › Article
-
Mark
Capturing breast cancers’ copy-number landscape in routine pathology : Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond
- Contribution to journal › Article
-
Mark
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK : a retrospective analysis
- Contribution to journal › Article
-
Mark
Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma : a case report
- Contribution to journal › Article
-
Mark
Copy number signatures in cervical samples enable early detection of high-grade serous ovarian carcinoma
(2025) SCRM 2025 - the 7th Swedish Cancer Research Meeting
- Contribution to conference › Poster
